Jon MBA - Biofrontera Vice Affairs
| BFRI Stock | USD 1.04 0.02 1.89% |
Executive
Jon MBA is Vice Affairs of Biofrontera
| Address | 120 Presidential Way, Woburn, MA, United States, 01801 |
| Phone | 781-245-1325 |
| Web | https://www.biofrontera-us.com |
Biofrontera Management Efficiency
The company has return on total asset (ROA) of (0.4024) % which means that it has lost $0.4024 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.4941) %, meaning that it created substantial loss on money invested by shareholders. Biofrontera's management efficiency ratios could be used to measure how well Biofrontera manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.84. The Biofrontera's current Return On Capital Employed is estimated to increase to -2.19. As of now, Biofrontera's Total Current Assets are increasing as compared to previous years. The Biofrontera's current Intangible Assets is estimated to increase to about 2.8 M, while Non Currrent Assets Other are projected to decrease to under 457.9 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Chris Bitterman | Cumberland Pharmaceuticals | 59 | |
| Marilyn Carlson | Evoke Pharma | 76 | |
| Eyal Broder | Painreform | N/A | |
| Mark CPA | Evoke Pharma | 47 | |
| Natalie May | Incannex Healthcare Ltd | N/A | |
| Stephen DMD | Painreform | N/A | |
| Antonia Assang | Regencell Bioscience Holdings | N/A | |
| Luigi MD | Incannex Healthcare Ltd | N/A | |
| Jean Marstiller | Cumberland Pharmaceuticals | 74 | |
| Malek Chamoun | Sunshine Biopharma Warrant | 39 | |
| Rita Keynan | Painreform | 55 | |
| Huang CFA | China Pharma Holdings | N/A | |
| Gene Esq | Shuttle Pharmaceuticals | N/A | |
| Erin Gull | Cumberland Pharmaceuticals | N/A | |
| Camilo Camacho | Procaps Group SA | 50 | |
| DMD MD | Evoke Pharma | 76 | |
| Timothy CPA | Shuttle Pharmaceuticals | 66 | |
| Carlos Russo | Procaps Group SA | 39 | |
| John Hamm | Cumberland Pharmaceuticals | 68 | |
| Marc Beaudoin | Sunshine Biopharma Warrant | 57 | |
| John Shulman | Petros Pharmaceuticals | 61 | |
Management Performance
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.4 |
Biofrontera Leadership Team
Elected by the shareholders, the Biofrontera's board of directors comprises two types of representatives: Biofrontera inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biofrontera. The board's role is to monitor Biofrontera's management team and ensure that shareholders' interests are well served. Biofrontera's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biofrontera's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Daniel JD, General Compliance | ||
| Jon MBA, Vice Affairs | ||
| Erica CPA, COO, CEO | ||
| Jeff Holm, Head Devel | ||
| Mark Baldyga, Head Marketing | ||
| Alycia Torres, Vice Administration | ||
| Hermann Luebbert, President CEO | ||
| Samantha Widdicombe, Senior Communications | ||
| Eugene III, Chief Officer | ||
| Hermann Lubbert, Ex Pres |
Biofrontera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biofrontera a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.49 | ||||
| Return On Asset | -0.4 | ||||
| Profit Margin | (0.38) % | ||||
| Operating Margin | (0.65) % | ||||
| Current Valuation | 6.33 M | ||||
| Shares Outstanding | 7.75 M | ||||
| Shares Owned By Insiders | 32.06 % | ||||
| Shares Owned By Institutions | 20.60 % | ||||
| Number Of Shares Shorted | 686.56 K | ||||
| Price To Book | 1.49 X |
Currently Active Assets on Macroaxis
When determining whether Biofrontera offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biofrontera's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biofrontera Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biofrontera Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biofrontera. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more detail on how to invest in Biofrontera Stock please use our How to Invest in Biofrontera guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biofrontera. If investors know Biofrontera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biofrontera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.16 | Revenue Per Share 11.573 | Quarterly Revenue Growth 0.34 | Return On Assets (0.40) | Return On Equity (1.49) |
The market value of Biofrontera is measured differently than its book value, which is the value of Biofrontera that is recorded on the company's balance sheet. Investors also form their own opinion of Biofrontera's value that differs from its market value or its book value, called intrinsic value, which is Biofrontera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biofrontera's market value can be influenced by many factors that don't directly affect Biofrontera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biofrontera's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biofrontera is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biofrontera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.